Re: Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

Sorry, there's nothing here.

Cite this paper

@article{Marshall2009RePI, title={Re: Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.}, author={Fray F. Marshall}, journal={European urology}, year={2009}, volume={56 2}, pages={399-400} }